Development and external validation of a machine learning model to predict diabetic nephropathy in T1DM patients in the real-world.

IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Zouxi Du, Xiaoning Liu, Jiayu Li, Hang Min, Yuhu Ma, Wenting Hua, Leyuan Zhang, Yue Zhang, Mengmeng Shang, Hui Chen, Hong Yin, Limin Tian
{"title":"Development and external validation of a machine learning model to predict diabetic nephropathy in T1DM patients in the real-world.","authors":"Zouxi Du, Xiaoning Liu, Jiayu Li, Hang Min, Yuhu Ma, Wenting Hua, Leyuan Zhang, Yue Zhang, Mengmeng Shang, Hui Chen, Hong Yin, Limin Tian","doi":"10.1007/s00592-024-02404-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Studies on machine learning (ML) for the prediction of diabetic nephropathy (DN) in type 1 diabetes mellitus (T1DM) patients are rare. This study focused on the development and external validation of an explainable ML model to predict the risk of DN among individuals with T1DM.</p><p><strong>Methods: </strong>This was a retrospective, multicenter study conducted across 19 hospitals in Gansu Province, China (No: 2022-473). In total, 1368 patients were eligible for analysis among 1633 collected T1DM patients from January 2016 to December 2023. Recursive feature elimination using random forest and fivefold cross-validation was conducted to identify key features. Among the 12 initial ML algorithms, the optimal ML model was developed and validated externally in a distinct population, and its predictive outcomes were explained via the SHapley additive exPlanations method, which offered personalized decision insights.</p><p><strong>Results: </strong>Among the 1368 T1DM patients, 324 had DN. The extreme gradient boosting (XGBoost) model, which achieved optimal performance with an AUC of 83% (95% confidence interval [CI]: 76‒89), was selected to predict the risk of DN among T1DM patients. The DN predictive model included variables such as T1DM duration, postprandial glucose (PPG), systolic blood pressure (SBP), glycated hemoglobin (HbA1c), serum creatinine (Scr) and low-density lipoprotein cholesterol (LDL-C). External validation confirmed the reliability of the model, with an AUC of 76% (95% CI: 70‒82).</p><p><strong>Conclusions: </strong>The ML prediction tool has potential for advancing early and precise identification of the risk of DN among T1DM patients. Although successful external validation indicated that the developed model can provide a promising strategy for clinical adoption and help improve patient outcomes through timely and accurate risk assessment, additional prospective data and further validation in diverse populations are necessary.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Diabetologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00592-024-02404-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Studies on machine learning (ML) for the prediction of diabetic nephropathy (DN) in type 1 diabetes mellitus (T1DM) patients are rare. This study focused on the development and external validation of an explainable ML model to predict the risk of DN among individuals with T1DM.

Methods: This was a retrospective, multicenter study conducted across 19 hospitals in Gansu Province, China (No: 2022-473). In total, 1368 patients were eligible for analysis among 1633 collected T1DM patients from January 2016 to December 2023. Recursive feature elimination using random forest and fivefold cross-validation was conducted to identify key features. Among the 12 initial ML algorithms, the optimal ML model was developed and validated externally in a distinct population, and its predictive outcomes were explained via the SHapley additive exPlanations method, which offered personalized decision insights.

Results: Among the 1368 T1DM patients, 324 had DN. The extreme gradient boosting (XGBoost) model, which achieved optimal performance with an AUC of 83% (95% confidence interval [CI]: 76‒89), was selected to predict the risk of DN among T1DM patients. The DN predictive model included variables such as T1DM duration, postprandial glucose (PPG), systolic blood pressure (SBP), glycated hemoglobin (HbA1c), serum creatinine (Scr) and low-density lipoprotein cholesterol (LDL-C). External validation confirmed the reliability of the model, with an AUC of 76% (95% CI: 70‒82).

Conclusions: The ML prediction tool has potential for advancing early and precise identification of the risk of DN among T1DM patients. Although successful external validation indicated that the developed model can provide a promising strategy for clinical adoption and help improve patient outcomes through timely and accurate risk assessment, additional prospective data and further validation in diverse populations are necessary.

开发机器学习模型并进行外部验证,以预测真实世界中 T1DM 患者的糖尿病肾病。
目的:有关机器学习(ML)预测1型糖尿病(T1DM)患者糖尿病肾病(DN)的研究很少见。本研究的重点是开发一种可解释的 ML 模型并进行外部验证,以预测 T1DM 患者的 DN 风险:这是一项回顾性多中心研究,在中国甘肃省的 19 家医院进行(编号:2022-473)。在2016年1月至2023年12月收集的1633名T1DM患者中,共有1368名患者符合分析条件。利用随机森林和五倍交叉验证进行递归特征消除,以确定关键特征。在12种初始ML算法中,开发了最佳ML模型,并在不同人群中进行了外部验证,其预测结果通过SHapley加法前计划方法进行了解释,从而提供了个性化的决策见解:在 1368 名 T1DM 患者中,有 324 人患有 DN。极端梯度提升(XGBoost)模型的AUC为83%(95%置信区间[CI]:76-89),达到最佳性能,被用于预测T1DM患者的DN风险。DN 预测模型包括 T1DM 病程、餐后血糖 (PPG)、收缩压 (SBP)、糖化血红蛋白 (HbA1c)、血清肌酐 (Scr) 和低密度脂蛋白胆固醇 (LDL-C) 等变量。外部验证证实了模型的可靠性,AUC 为 76%(95% CI:70-82):ML预测工具具有推动早期精确识别T1DM患者DN风险的潜力。虽然成功的外部验证表明所开发的模型可以为临床应用提供一种有前景的策略,并通过及时准确的风险评估帮助改善患者的预后,但还需要更多的前瞻性数据和在不同人群中的进一步验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Diabetologica
Acta Diabetologica 医学-内分泌学与代谢
CiteScore
7.30
自引率
2.60%
发文量
180
审稿时长
2 months
期刊介绍: Acta Diabetologica is a journal that publishes reports of experimental and clinical research on diabetes mellitus and related metabolic diseases. Original contributions on biochemical, physiological, pathophysiological and clinical aspects of research on diabetes and metabolic diseases are welcome. Reports are published in the form of original articles, short communications and letters to the editor. Invited reviews and editorials are also published. A Methodology forum, which publishes contributions on methodological aspects of diabetes in vivo and in vitro, is also available. The Editor-in-chief will be pleased to consider articles describing new techniques (e.g., new transplantation methods, metabolic models), of innovative importance in the field of diabetes/metabolism. Finally, workshop reports are also welcome in Acta Diabetologica.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信